{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:30:16Z","timestamp":1768012216682,"version":"3.49.0"},"reference-count":55,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2023]]},"DOI":"10.3960\/jslrt.23003","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T22:12:50Z","timestamp":1687903970000},"page":"58-64","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostic approach for classic Hodgkin lymphoma in small samples with an emphasis on PD-L1 expression and EBV harboring in tumor cells: a brief review from morphology to biology"],"prefix":"10.3960","volume":"63","author":[{"given":"Taishi","family":"Takahara","sequence":"first","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Sakakibara","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Tsuyuki","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Satou","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Roemer MGM, Advani RH, Ligon AH et al.<\/i> PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016; 34: 2690-2697.","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Elsayed AA, Asano N, Ohshima K et al.<\/i> Prognostic significance of CD20 expression and Epstein-Barr virus (EBV) association in classical Hodgkin lymphoma in Japan: a clinicopathologic study. Pathol Int. 2014; 64: 336-345.","DOI":"10.1111\/pin.12175"},{"key":"3","unstructured":"3 Swerdlow SH. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, International Agency for Research on Cancer. 2017; pp. 424-442."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Campo E, Jaffe ES, Cook JR et al.<\/i> The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140: 1229-1253.","DOI":"10.1182\/blood.2022015851"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Armitage JO, Gale RP, Jaffe ES. Lymphoma Nomenclature \u2010 What\u2019s in a name? Br J Haematol. 2022; 197: 539-543.","DOI":"10.1111\/bjh.18063"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Sakakibara A, Kohno K, Eladl AE et al.<\/i> Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells. Histopathology. 2018; 72: 1156-1163.","DOI":"10.1111\/his.13475"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Green MR, Monti S, Rodig SJ et al.<\/i> Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010; 116: 3268-3277.","DOI":"10.1182\/blood-2010-05-282780"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Green MR, Rodig S, Juszczynski P et al.<\/i> Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012; 18: 1611-1618.","DOI":"10.1158\/1078-0432.CCR-11-1942"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Van Roosbroeck K, Ferreiro JF, Tousseyn T et al.<\/i> Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies. Genes Chromosomes Cancer. 2016; 55: 428-441.","DOI":"10.1002\/gcc.22345"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Liu Y, Abdul Razak FR, Terpstra M et al.<\/i> The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing. Leukemia. 2014; 28: 2248-2251.","DOI":"10.1038\/leu.2014.201"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Wienand K, Chapuy B, Stewart C et al.<\/i> Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv. 2019; 3: 4065-4080.","DOI":"10.1182\/bloodadvances.2019001012"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 D\u00fcrkop H, Latza U, Hummel M et al.<\/i> Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin\u2019s disease. Cell. 1992; 68: 421-427.","DOI":"10.1016\/0092-8674(92)90180-K"},{"key":"13","unstructured":"13 von Wasielewski R, Mengel M, Fischer R et al.<\/i> Classical Hodgkin\u2019s disease. Clinical impact of the immunophenotype. Am J Pathol. 1997; 151: 1123-1130."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Carbone A, Gloghini A, Carlo-Stella C. Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade? Blood. 2018; 132: 17-22.","DOI":"10.1182\/blood-2018-02-833806"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Panjwani PK, Charu V, DeLisser M et al.<\/i> Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. Hum Pathol. 2018; 71: 91-99.","DOI":"10.1016\/j.humpath.2017.10.029"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Gerhard-Hartmann E, Goergen H, Br\u00f6ckelmann PJ et al.<\/i> 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. Br J Haematol. 2022; 196: 116-126.","DOI":"10.1111\/bjh.17793"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Volaric A, Bacchi CE, Gru AA. PD-1 and PD-L1 Immunohistochemistry as a diagnostic tool for classic Hodgkin lymphoma in small-volume biopsies. Am J Surg Pathol. 2020; 44: 1353-1366.","DOI":"10.1097\/PAS.0000000000001524"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Venkataraman G, Song JY, Tzankov A et al.<\/i> Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival. Blood. 2013; 121: 1795-1804.","DOI":"10.1182\/blood-2012-06-439455"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Ansell SM, Lesokhin AM, Borrello I et al.<\/i> PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015; 372: 311-319.","DOI":"10.1056\/NEJMoa1411087"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Chen R, Zinzani PL, Fanale MA et al.<\/i> Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017; 35: 2125-2132.","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Aoki T, Chong LC, Takata K et al.<\/i> Single-cell profiling reveals the importance of CXCL13\/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma. Proc Natl Acad Sci USA. 2021; 118: e2105822118.","DOI":"10.1073\/pnas.2105822118"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Lawson NL, Dix CI, Scorer PW et al.<\/i> Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies. Mod Pathol. 2020; 33: 518-530.","DOI":"10.1038\/s41379-019-0372-z"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Takahara T, Satou A, Ishikawa E et al.<\/i> Clinicopathological analysis of neoplastic PD-L1-positive EBV+ diffuse large B cell lymphoma, not otherwise specified, in a Japanese cohort. Virchows Arch. 2021; 478: 541-552.","DOI":"10.1007\/s00428-020-02901-w"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum Pathol. 2016; 54: 17-24.","DOI":"10.1016\/j.humpath.2016.03.005"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Kataoka K, Miyoshi H, Sakata S et al.<\/i> Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia. 2019; 33: 1687-1699.","DOI":"10.1038\/s41375-019-0380-5"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Kohno K, Sakakibara A, Iwakoshi A et al.<\/i> Syncytial variant of classic Hodgkin lymphoma: four cases diagnosed with the aid of CD274\/programmed cell death ligand 1 immunohistochemistry. Pathol Int. 2020; 70: 108-115.","DOI":"10.1111\/pin.12888"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Sakakibara A, Kohno K, Ishikawa E et al.<\/i> Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review. J Clin Exp Hematop. 2021; 61: 182-191.","DOI":"10.3960\/jslrt.21003"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Chang KC, Khen NT, Jones D, Su IJ. Epstein-Barr virus is associated with all histological subtypes of Hodgkin lymphoma in Vietnamese children with special emphasis on the entity of lymphocyte predominance subtype. Hum Pathol. 2005; 36: 747-755.","DOI":"10.1016\/j.humpath.2005.05.003"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Lee JH, Kim Y, Choi JW, Kim YS. Prevalence and prognostic significance of Epstein-Barr virus infection in classical Hodgkin\u2019s lymphoma: a meta-analysis. Arch Med Res. 2014; 45: 417-431.","DOI":"10.1016\/j.arcmed.2014.06.001"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Asano N, Kinoshita T, Ohshima K et al.<\/i> Clinicopathological features of nodular sclerosis-type classical Hodgkin lymphoma in the elderly: multicenter study of Hodgkin lymphoma in Japan. Blood. 2010; 116: 2677.","DOI":"10.1182\/blood.V116.21.2677.2677"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Tiacci E, Ladewig E, Schiavoni G et al.<\/i> Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood. 2018; 131: 2454-2465.","DOI":"10.1182\/blood-2017-11-814913"},{"key":"32","unstructured":"32 Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene. 1995; 10: 549-560."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Schmitz R, Hansmann ML, Bohle V et al.<\/i> TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med. 2009; 206: 981-989.","DOI":"10.1084\/jem.20090528"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Mancao C, Hammerschmidt W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood. 2007; 110: 3715-3721.","DOI":"10.1182\/blood-2007-05-090142"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Montes-Moreno S, Odqvist L, Diaz-Perez JA et al.<\/i> EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol. 2012; 25: 968-982.","DOI":"10.1038\/modpathol.2012.52"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Nicolae A, Pittaluga S, Abdullah S et al.<\/i> EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood. 2015; 126: 863-872.","DOI":"10.1182\/blood-2015-02-630632"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Xing W, Dresser K, Zhang R et al.<\/i> PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget. 2016; 7: 59976-59986.","DOI":"10.18632\/oncotarget.11045"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Bourbon E, Maucort-Boulch D, Fontaine J et al.<\/i> Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. Blood Adv. 2021; 5: 3227-3239.","DOI":"10.1182\/bloodadvances.2021004515"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Marafioti T, Hummel M, Foss HD et al.<\/i> Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000; 95: 1443-1450.","DOI":"10.1182\/blood.V95.4.1443.004k55_1443_1450"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Kanzler H, K\u00fcppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin\u2019s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996; 184: 1495-1505.","DOI":"10.1084\/jem.184.4.1495"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Huntington ND, Xu Y, Puthalakath H et al.<\/i> CD45 links the B cell receptor with cell survival and is required for the persistence of germinal centers. Nat Immunol. 2006; 7: 190-198.","DOI":"10.1038\/ni1292"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Asano N, Kinoshita T, Tamaru J et al.<\/i> Cytotoxic molecule-positive classical Hodgkin\u2019s lymphoma: a clinicopathological comparison with cytotoxic molecule-positive peripheral T-cell lymphoma of not otherwise specified type. Haematologica. 2011; 96: 1636-1643.","DOI":"10.3324\/haematol.2011.041079"},{"key":"43","unstructured":"43 Karube K, Takatori M, Sakihama S et al.<\/i> Clinicopathological features of adult T-cell leukemia\/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells. Blood Adv. 2021; 5: 198-206."},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Tsuyama N, Noguchi M, Asaka R et al.<\/i> Hodgkinoid histiocytosis: an atypical nodal CD30 and S100 \u2010positive histiocytosis with eosinophilia. Histopathology. 2022; 81: 371-379.","DOI":"10.1111\/his.14718"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Parente P, Zanelli M, Sanguedolce F, Mastracci L, Graziano P. Hodgkin Reed-Sternberg-like cells in non-Hodgkin lymphoma. Diagnostics (Basel). 2020; 10: 1019.","DOI":"10.3390\/diagnostics10121019"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Asano N, Oshiro A, Matsuo K et al.<\/i> Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin\u2019s lymphoma: a clinicopathologic study. J Clin Oncol. 2006; 24: 4626-4633.","DOI":"10.1200\/JCO.2006.06.5342"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Shen J, Li S, Medeiros LJ et al.<\/i> PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. Mod Pathol. 2020; 33: 324-333.","DOI":"10.1038\/s41379-019-0336-3"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Zhang Q, Kim DH, Xu Y, Wang W, Medeiros LJ. Clinicopathological features of syncytial variant nodular sclerosis Hodgkin lymphoma. Hum Pathol. 2022; 119: 105-113.","DOI":"10.1016\/j.humpath.2021.11.007"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Kohno K, Suzuki Y, Harada T et al.<\/i> Nodal diffuse large B\u2010cell lymphoma with neoplastic PD\u2010L1 positivity, but without EBV association: three cases highlighting an aspect of gray zone lymphoma. Pathol Int. 2020; 70: 695-697.","DOI":"10.1111\/pin.12982"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Elsayed AA, Satou A, Eladl AE et al.<\/i> Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a clinicopathological study of 14 Epstein-Barr virus-positive cases. Histopathology. 2017; 70: 579-594.","DOI":"10.1111\/his.13100"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Huppmann AR, Nicolae A, Slack GW et al.<\/i> EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults. Am J Surg Pathol. 2014; 38: 316-324.","DOI":"10.1097\/PAS.0000000000000107"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Daroontum T, Kohno K, Eladl AE et al.<\/i> Comparison of Epstein-Barr virus-positive mucocutaneous ulcer associated with treated lymphoma or methotrexate in Japan. Histopathology. 2018; 72: 1115-1127.","DOI":"10.1111\/his.13464"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Megahed NA, Kohno K, Sakakibara A et al.<\/i> Anaplastic variant of diffuse large B\u2010cell lymphoma: reappraisal as a nodal disease with sinusoidal involvement. Pathol Int. 2019; 69: 697-705.","DOI":"10.1111\/pin.12871"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Kume A, Shinozaki-Ushiku A, Kunita A, Kondo A, Ushiku T. Enhanced PD-L1 expression in LMP1-positive cells of Epstein-Barr virus-associated malignant lymphomas and lymphoproliferative disorders: a single-cell resolution analysis with multiplex fluorescence immunohistochemistry and in situ hybridization. Am J Surg Pathol. 2022; 46: 1386-1396.","DOI":"10.1097\/PAS.0000000000001919"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Eladl AE, Satou A, Elsayed AA et al.<\/i> Clinicopathological study of 30 cases of peripheral T-cell lymphoma with Hodgkin and Reed-Sternberg-like B-cells from Japan. Am J Surg Pathol. 2017; 41: 506-516.","DOI":"10.1097\/PAS.0000000000000813"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/2\/63_23003\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T04:51:53Z","timestamp":1690001513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/2\/63_23003\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.23003","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"23003"}}